insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

CMMB · Chemomab Therapeutics Ltd. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · CMMB

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ4 '25Q2 '25Q4 '24Q2 '24Q4 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D---$2.93M-$5.02M$6.89M-$5.42M$2.91M
SG&A---$840.0K-$3.17M$2.16M-$2.89M$3.34M
Total Operating Expenses---$3.77M-$8.20M$9.05M-$8.32M$6.25M
D&A------$16.0K---
Operating Income---($3.63M)-($7.94M)($8.73M)-($8.08M)($2.77M)
Interest Expense----------
Income Tax---$0-$34.0K$0-$0($544.0K)
Net Income-($2.06M)-($3.87M)-($7.97M)($8.75M)-($8.08M)($6.19M)
EPS - Basic---$0.05-$0.14$0.09-$0.14$0.11
EPS - Diluted---$0.05-$0.14$0.16-$0.14$0.11

Balance Sheet

Line itemQ4 '25Q2 '25Q4 '24Q2 '24Q4 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22
Cash & Equivalents$7.56M$5.45M$6.07M$5.04M$9.29M$10.38M$20.77M$13.52M$10.74M$9.88M
Accounts Receivable----------
Inventory----------
Accounts Payable$485.0K$378.0K$666.0K$1.11M$516.0K$2.35M$2.22M$1.69M$1.25M$1.43M
Current Assets$13.43M$10.61M$16.04M$13.46M$20.90M$27.70M$33.78M$41.74M$48.73M$54.83M
Total Assets$13.81M$11.13M$16.96M$14.54M$22.15M$28.85M$35.01M$43.06M$50.22M$56.38M
Current Liabilities$1.48M$1.43M$3.22M$4.31M$4.84M$6.83M$7.00M$6.75M$5.48M$4.39M
Long-term Debt----------
Total Liabilities$1.48M$1.43M$3.43M$4.56M$5.15M$6.86M$7.06M$6.84M$5.59M$4.54M
Stockholders' Equity$12.33M$9.70M$13.54M$13.33M$17.00M$21.99M$27.95M$36.22M$44.62M$51.84M
Retained Earnings($111.62M)($108.00M)($102.62M)($96.18M)($88.68M)($80.54M)($72.57M)($63.82M)($55.55M)($47.47M)

Cash Flow

Line itemQ4 '25Q2 '25Q4 '24Q2 '24Q4 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22
Operating Cash Flow------($7.19M)---
Investing Cash Flow------$14.43M---
Financing Cash Flow------$0---
CapEx------$1.0K---
Free Cash Flow------($7.19M)---

Ratios

MetricQ4 '25Q2 '25Q4 '24Q2 '24Q4 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income------0.82---
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets--18.5%--26.6%--27.6%-25.0%--16.1%-11.0%
Return on equity--21.2%--29.0%--36.2%-31.3%--18.1%-11.9%
Return on invested capital----------
Liquidity
Current ratio9.087.424.983.124.324.064.836.188.9012.48
Quick ratio9.087.424.983.124.324.064.836.188.9012.48
Cash ratio5.123.811.891.171.921.522.972.001.962.25
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.121.151.251.091.301.311.251.191.131.09
Liabilities / Assets0.110.130.200.310.230.240.200.160.110.08
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E---70.2x-36.5x39.8x-71.1x137.0x
P / B---78.3x-53.0x51.9x-51.1x65.1x
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)---54.2%--186.5%----
Net income growth (YoY)-46.8%-51.5%--28.8%-71.5%--172.2%-123.5%
EPS growth (YoY)----63.9%-33.3%----
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)-------92.9%---
FCF CAGR (5y)----------
Book value growth (YoY)-8.9%-27.2%-20.4%-39.4%-53.1%-57.6%-51.2%-41.1%-31.9%-23.8%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Chemomab Therapeutics Ltd. against the 5 most active filers in the same SIC group.